Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals develops drugs for advanced and refractory cancers in Taiwan. Its pipeline includes GNTbm-38, an epigenetic immune-activating drug for cancer immunotherapy, and GNTbm-TKI, an inhibitor targeting TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppression, and anti-angiogenesis. It is also developing Kepida for HR+/HER2- advanced breast cancer and peripheral T-cell lymphoma. Formerly GNT Biotech & Medicals Corporation, the company was incorporated in 2013 and is based in Taipei, Taiwan.